A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor
activity in advanced or metastatic cholangiocarcinoma patients with Fibroblast Growth Factor
receptor (FGFR) genetic alterations.